Biologics in Pediatric Inflammatory Bowel Disease
Pediatric Annals
|February 14, 2022
Summary
Pediatric inflammatory bowel diseases (IBD) are increasingly treated with biologics, which are targeted antibody therapies. General pediatricians must understand the potential complications and adverse effects associated with these treatments in children with IBD.
Area of Science:
- Pediatric Gastroenterology
- Immunology
- Pharmacology
Background:
- Inflammatory bowel diseases (IBD), including Crohn's disease and ulcerative colitis, are common in pediatric populations.
- While managed by specialists, general pediatricians frequently encounter children with IBD.
- Understanding advanced treatment options is crucial for comprehensive pediatric care.
Purpose of the Study:
- To review the application of biologics (targeted antibody treatments) in pediatric IBD.
- To outline potential complications and adverse effects of biologic therapy in children.
- To equip general pediatricians with knowledge for managing pediatric IBD patients on biologics.
Main Methods:
- Literature review of biologics used in pediatric IBD.
- Analysis of reported complications and adverse events.
- Synthesis of clinical considerations for general pediatricians.
Main Results:
- Biologics represent a significant therapeutic advancement for pediatric IBD.
- Specific targeted antibody treatments have demonstrated efficacy in managing pediatric IBD.
- Potential adverse effects and complications require careful monitoring by healthcare providers.
Conclusions:
- Biologic therapies are integral to modern pediatric IBD management.
- Pediatricians must be aware of the safety profile and monitoring requirements for biologics.
- Effective management necessitates collaboration between pediatricians and gastroenterologists.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
220
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
220
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
249
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
249
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
232
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
232
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
282
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
01:30Inflammatory Bowel Disease II: Crohn's Disease
435
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
435
01:30Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
443
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
443